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Development of New Vaccines for Tuberculosis
Recommendations of the Advisory Council
for the Elimination of Tuberculosis (ACET)
Summary
Tuberculosis (TB) remains a major, global public health problem, particularly
in low-income countries. Better application of current diagnostic, treatment, and
prevention strategies could lead to gradual decreases in the disease, but elimi-
nating TB completely in the United States and internationally will require new
tools. The greatest impact could come from a new vaccine, and recent techno-
logical advances have provided the basis for new vaccine development.
However, sustained support is required to move the research from the labora-
tory to field trials of vaccines and to implement new vaccine programs.
Recognizing the importance of TB vaccines, the Advisory Council for the Elimi-
nation of Tuberculosis (ACET) recommends that public agencies and vaccine
manufacturers develop a comprehensive, consensual strategy to achieve these
goals. This report outlines the elements that should be considered in devising a
strategic plan for vaccine development.
INTRODUCTION
Interest in the development of new vaccines for tuberculosis (TB) has increased
in recent years as the disease continues to be a major, global public health problem.
Mycobacterium tuberculosis kills more adults each year than any other single patho-
gen, according to the World Health Organization (WHO) Global Tuberculosis Pro-
gramme (1 ). The World Bank estimates that the disease accounts for >25% of avoid-
able adult deaths in developing countries (2 ). Moreover, the global number of TB
cases is expected to continue to increase (3 ), particularly in countries where the hu-
man immunodeficiency virus (HIV) infection is epidemic, unless diagnostic and
treatment strategies are applied widely and effectively.
This pandemic is contributing to the TB burden in the United States. In 1997, nearly
40% of new U.S. cases occurred in persons born in other countries (4 ). Like Canada
and several European countries, the United States is expected soon to have more TB
cases among foreign-born persons than native-born persons.
CURRENT CONTROL MEASURES
Some TB control strategies, including widespread use of bacille Calmette-Guérin
(BCG) vaccine and the provision of drugs without supervised treatment, have had little
impact on the disease and have worsened it in some cases. The most effective control
measure is curative treatment of patients with infectious pulmonary tuberculosis
(i.e., those with acid-fast bacilli [AFB] found on microscopic examination of sputum
smears). Although WHO estimates that widespread application of its directly
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observed treatment, short-course (DOTS) strategy* could decrease the global TB bur-
den by 50% within 10 years (5 ), data to support this proposition are lacking. The DOTS
strategy also requires a largely vertical, complex system (e.g., specialized staff at the
central level, a system of diagnostic and treatment centers, and frequent training and
supervision of field staff) that could be difficult to sustain in many areas without con-
tinuing donor assistance. This drawback, as well as reliance on antiquated tools (e.g.,
microscopy and chest radiography for diagnosis and treatment regimens of at least
6 months’ duration) suggests that this approach might not have the anticipated im-
pact. In 1995, programs that had implemented the DOTS strategy covered <25% of the
world’s population (6 ), and WHO announced this year that its Year 2000 TB objectives
would not be met because of slow implementation of DOTS (7 ). 
Although BCG vaccine is the most widely administered of all vaccines and has the
highest coverage of any vaccine in the WHO Expanded Programme on Immunization,
it appears to have had little epidemiologic impact on TB (8 ). Both randomized
placebo-controlled clinical trials and retrospective case-control and cohort studies
have demonstrated a wide variation in vaccine efficacy, ranging from 80% to zero (9 ).
The largest and most recent prospective randomized trial, the Chingleput study
in southern India, failed to demonstrate any protection overall (10 ). These studies
have indicated, however, that BCG confers protection against serious forms of child-
hood TB (e.g., disseminated and meningeal TB) that are associated with high mortality
rates. More recent studies have demonstrated that BCG vaccine also protects against
the development of leprosy (11,12 ). Despite its shortcomings and because of its bene-
ficial effect in children and against leprosy, BCG vaccine likely will remain a com-
ponent of childhood vaccination strategies in low-income countries. However,
because of questions about the vaccine’s efficacy and because it induces dermal
hypersensitivity to purified protein derivative (PPD) tuberculin in most recipients, BCG
has never been recommended for programmatic use in the United States.
ELIMINATING TUBERCULOSIS
During the past decade, several countries with low TB incidence rates, including
the United States, have embarked on plans to eliminate the disease as a public health
problem (13,14 ). In CDC’s 1989 Strategic Plan for the Elimination of Tuberculosis in
the United States, ACET defined elimination as achieving an incidence rate of reported
cases of fewer than 1 per million (i.e., a 74-fold reduction from the 1997 U.S. case rate).
During development of the U.S. plan, CDC recognized that new diagnostic, treatment,
and prevention technologies would be needed to achieve this goal because of the
limitations of current methods.
For example, even when current screening and diagnostic technologies are applied
optimally, many patients with newly diagnosed TB already have spread the infection
to their closest contacts before they are identified and treated. Environmental control
methods (e.g., ventilation and ultraviolet radiation) have reduced TB transmission in
some settings, most notably hospitals, but these measures cannot be applied easily
*The essential elements of the DOTS strategy are a) political consensus that tuberculosis control
should be given a high priority; b) passive case-finding based on sputum smear microscopy;
c) use of standardized, short-course treatment regimens administered under direct observation;
d) a secure supply of drugs and equipment; and e) supervision with regular monitoring of
treatment and case-finding results.
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in environments where most transmission likely occurs (e.g., households of infectious
patients, nursing homes, prisons, jails, homeless shelters, and other community
settings). 
CDC also has advocated preventive chemotherapy — treating persons with M. tu-
berculosis infection at risk for developing active disease — as an important inter-
vention strategy. Theoretically, preventive therapy could play a major role in TB elimi-
nation. However, the problems of nonadherence and drug toxicity and the difficulties
in identifying those infected persons at highest risk for disease limit the effectiveness
of this strategy. Some progress has been made, as exemplified by the recent studies
of rifampin-based, short-course preventive therapy, but curative treatment and pre-
ventive therapy as practiced are not likely to eliminate TB.
Without a breakthrough in intervention strategy (i.e., a new TB vaccine), the global
toll of TB will not be reduced substantially, nor will the disease be eliminated in the
United States and other low-incidence countries where TB cases continue to emerge
from the pool of previously infected persons. Research advances of the recent past
have increased the likelihood that a new vaccine will be developed soon.
PROGRESS IN VACCINE DEVELOPMENT
A major research effort is being made to develop new tuberculosis vaccines. Much
of this work is aimed at improved understanding of the immunopathogenesis of TB by
studying both the infecting organism and its human host. Researchers have se-
quenced the complete genome of M. tuberculosis (15 ), which will provide new
opportunities to address questions of virulence, pathogenesis, and persistence (i.e.,
the ability of bacilli to achieve long-lasting dormancy following infection). Researchers
also have more knowledge of both host and microbial genetic factors related to
increased resistance and susceptibility to TB (16,17 ) and are working to better under-
stand the human protective immune response to the disease (18 ).
At the same time, new vaccine candidates (e.g., subunit vaccines, DNA vaccines,
and attenuated strains of living mycobacteria) are being developed and tested in ani-
mal models (19 ). Within the next few years, several candidate vaccines should be
available for human testing.
NEEDS AND RECOMMENDATIONS
Several critical steps must be taken to reach the goal of developing a new vaccine
and establishing its use in public health programs. ACET recommends the following
initial actions:
• Develop a consensus among public funding agencies and vaccine manufacturers
that a new TB vaccine is an urgent public health priority.
• Establish a sustained commitment of both private and public-sector funds over
several decades to support intramural and extramural research. 
Much of this work logically will fall within the scope of the National Institutes
of Health (NIH), but also should be supported by CDC; the Food and Drug Admini-
stration (FDA), which is part of the Public Health Service (PHS); and the U.S.
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Agency for International Development (USAID). International partners like WHO
should be involved so that research initiatives can be expanded to focus on all
aspects of TB vaccine development.
To achieve these goals, dialogue must be increased between U.S. public funding
agencies, international health organizations, vaccine manufacturers, and other
interested parties (e.g., public health and medical communities). Although a new
vaccine could be developed largely through public-sector support, the ultimate
feasibility of production and global distribution depends on establishing an ongo-
ing partnership with the pharmaceutical industry. Collaborations should be
sought domestically and internationally with private and public-sector partners
to advance a vaccine development strategy. Establishing a TB vaccine task force
composed of these partners could provide guidance and advocacy in this area.
• Develop a comprehensive strategic plan for vaccine development. Although sev-
eral national and international meetings have addressed vaccine development in
recent years, a comprehensive strategy has not been formulated. The PHS
should play a major role in developing this plan by establishing a projected time-
line and estimates of resource needs, outlining specific steps that need to be
taken, and defining the roles and responsibilities of the interested parties (e.g.,
the public sector, industry, and academia). This process was started earlier in
1998 when the NIH’s National Institute for Allergy and Infectious Diseases spon-
sored the Blueprint for TB Vaccine Development Workshop.
• Establish close collaboration between CDC, FDA, and NIH to support implemen-
tation of clinical vaccine trials, as recommended in the 1992 National Action Plan
to Combat Multidrug-Resistant Tuberculosis (20 ).
Relationships also must be developed and fostered with international organiza-
tions (e.g., WHO and the International Union Against Tuberculosis and Lung
Disease), funding agencies (e.g., USAID and the World Bank), and vaccine manu-
facturers. Representatives of these organizations should form a working group to
develop protocols for field-testing candidate vaccines. Vaccine trial sites should
be identified in both the United States and high-incidence countries, and prepara-
tions for clinical testing should begin as soon as possible. However, major
expenditures should not be committed too far in advance of the availability of
appropriate vaccine candidates.
• Increase basic research. Researchers need to define what host factors protect
persons from TB infection and disease development, and they need to discover
how the properties of the tubercle bacillus permit it to survive years after the
establishment of infection. Researchers should organize studies in the United
States that use hypothesis-generating protocols to link specific epidemiology,
human immune status and response, and other physiological responses to TB
infection, TB disease, and the bacteriology of infecting organisms.
To facilitate vaccine trials, researchers need to determine human correlates
of protection against TB. The major endpoint for clinical trials would be the devel-
opment of TB, which would make the trials long and costly to conduct. Correlates
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of protection (e.g., lymphocyte proliferation or cytokine production in response
to antigenic stimulation) have never been validated in humans. Although
researchers have long thought that induction of responsiveness to PPD by BCG
vaccine correlated with vaccine efficacy, an analysis of clinical trials has dis-
proved this theory (21 ). However, putative surrogate markers of protection could
be evaluated in initial vaccine trials and, if shown to correlate with protection,
could be used to select and test newer vaccine candidates for further study. Tri-
als also are needed to establish vaccine safety and efficacy in persons with HIV
infection.
• Establish consensus on what characteristics are desirable in a new vaccine. For
example, any new vaccine should be relatively free of side effects and safe when
administered to immunocompromised persons (e.g., persons with HIV infection).
It should be, but does not have to be, non-living. Ideally, the vaccine should not
lead to hypersensitivity to PPD, which would make tuberculin testing invalid in
vaccinated persons. The vaccine should protect against disease resulting from
subsequent infection (i.e., preexposure), as well as endogenous reactivation of
earlier infection (i.e., postinfection). Although it is commonly thought that a new
preexposure vaccine is needed to replace BCG, a postinfection vaccine could be
more effective, especially in countries like the United States where the majority
of TB cases occur in persons with remote infection. Given the limitations of pre-
ventive therapy, an effective postinfection vaccine could be the most important
new tool to help eliminate TB in the United States. In high-incidence countries, a
postinfection vaccine could be administered to adults in high-risk groups (e.g.,
health-care workers), and wide application could have a major global impact.
Before a new vaccine can be tested on humans, researchers must prove that it is
safe in animals and that it induces an immune response. Although not an abso-
lute requirement, a new vaccine also should demonstrate protection against TB
in animal models. No surrogate marker of protection has been validated in ani-
mal models, so protection can only be demonstrated by response to a challenge
from a dose of virulent tubercle bacilli. Because no models of dormant TB infec-
tion exist to test postinfection vaccines, additional research is needed in this area.
CONCLUSION
Signs of progress are appearing in TB vaccine development. To build the needed
consensus for a strategic approach and the partnerships required for success, the
National Vaccine Program Office (NVPO) is sponsoring an international symposium
on TB vaccine development and evaluation in 1998. The primary objectives of
the meeting are to stimulate the field of TB vaccinology, build partnerships among
organizations essential to the successful development of vaccines, and help imple-
ment a universal strategy for vaccine development and evaluation. These objectives
represent important first steps to eliminating TB as a global health problem.
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